Evidence map›Paper›PMID 34738872›Full record

ArticleBioengineered2022

miR-877-3p inhibits tumor growth and angiogenesis of osteosarcoma through fibroblast growth factor 2 signaling.

Mingji Chen, Zhi Li, Lei Cao, Chi Fang, Rufeng Gao, Chao Liu

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Exosomes loaded with miR-665 inhibit the progression of osteosarcomaAmerican journal of translational research · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Mingji ChenDepartment of Orthopedics, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
Zhi LiDepartment of Orthopedics, Shanghai Songjiang District Central Hospital, Shanghai, China.
Lei CaoDepartment of Orthopedics, Shanghai Songjiang District Central Hospital, Shanghai, China.
Chi FangDepartment of Gynecologic Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Rufeng GaoDepartment of Orthopedics, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
Chao LiuDepartment of Radiology, Shanghai Songjiang District Central Hospital, Shanghai, China.
Songjiang District Central Hospital · CNFudan University · CNFudan University Shanghai Cancer Center · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common high-grade malignant bone tumor in teenagers. MicroRNAs can function as posttranscriptional regulators of gene expression, playing critical roles in cancer dev-877-3p in OS. Quantitative real-time RT-PCR was carried out for detecting miR-877-3p expression in OS. The effects of miR-877-3p on proliferation was analyzed via MTT, colony formation, and flow cytometry assays. Angiogenesis of endothelial cells were investigated by wound healing and tube formation assay. Gene profiling based on PCR array and luciferase reporter assay were conducted to determine target genes of miR-877-3p. In-vivo study was used to determine the effects of miR-877-3p on the tumor growth. The expression of miR-877-3p was markedly downregulated in OS tissues and cell lines. Low expression of miR-877-3p predicts poor prognosis of OS patients. miR-877-3p overexpression was found to inhibit the proliferation of OS cell lines. The angiogenesis assays showed that miR-877-3p attenuated the angiogenesis. Further mechanism studies showed that miR-877-3p can reduce (Fibroblast Growth Factor 2) FGF2 expression in OS cells by binding to the 3'UTR end of FGF2. Moreover, increased expression of miR-877-3p was responsible for the inhibition of tumor growth and angiogenesis. Taken together, our findings indicated that miR-877-3p might exhibit tumor suppressive role by targeting FGF2 signaling, which may serve as potential target for OS.

Indexed as

Bone NeoplasmsMicroRNAsOsteosarcomaAdolescentCell Line, TumorCell MovementCell ProliferationEndothelial CellsFibroblast Growth Factor 2HumansFibroblast Growth Factor 2MicroRNAsMIRN877 microRNA, humanangiogenesisfgf2Mir-877-3posteosarcomaproliferation

Identifiers

PMID34738872
PMCPMC9162015
OpenAlexW3208382895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.